Search research articles
Contact Us
Filters
Showing results (61-70 of 81) with videos related to
Page
of 9
Sort By:
Cancer Immunology Research
|
February 19, 2022
Holistic Characterization of Tumor Monocyte-to-Macrophage Differentiation Integrates Distinct Immune Phenotypes in Kidney Cancer
Adriana M Mujal, Alexis J Combes, Arjun A Rao, et al.
Urology
|
December 5, 2020
Liposomal Bupivacaine Decreases Postoperative Length of Stay and Opioid Use in Patients Undergoing Radical Cystectomy
Carissa E Chu, Lauren Law, Kyle Zuniga, et al.
Molecular Cancer Research : MCR
|
March 4, 2020
TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer
Sharada Mokkapati, Sima P Porten, Vikram M Narayan, et al.
European Urology
|
August 18, 2023
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605
Peter C Black, Catherine M Tangen, Parminder Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Carissa E Chu, Martin Sjöström, Emily A Egusa, et al.
The Journal of Urology
|
October 25, 2021
Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons
Meera R Chappidi, Heiko Yang, Maxwell V Meng, et al.
BMC Cancer
|
November 19, 2023
Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer
John L Gore, Erika M Wolff, Bryan A Comstock, et al.
European Urology Oncology
|
June 30, 2026
Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab
Kevin R Reyes, Ryan Zhu, Cameron Herberts, et al.
Nature Communications
|
June 17, 2025
Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression
Heiko Yang, Hanbing Song, Elizabeth Yip, et al.
Cancers
|
April 13, 2024
Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry
Seyedeh-Sanam Ladi-Seyedian, Alireza Ghoreifi, Badrinath Konety, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 81) with videos related to
Sort By:
Page
of 9
Cancer Immunology Research
|
February 19, 2022
Holistic Characterization of Tumor Monocyte-to-Macrophage Differentiation Integrates Distinct Immune Phenotypes in Kidney Cancer
Adriana M Mujal, Alexis J Combes, Arjun A Rao, et al.
Urology
|
December 5, 2020
Liposomal Bupivacaine Decreases Postoperative Length of Stay and Opioid Use in Patients Undergoing Radical Cystectomy
Carissa E Chu, Lauren Law, Kyle Zuniga, et al.
Molecular Cancer Research : MCR
|
March 4, 2020
TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer
Sharada Mokkapati, Sima P Porten, Vikram M Narayan, et al.
European Urology
|
August 18, 2023
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605
Peter C Black, Catherine M Tangen, Parminder Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Carissa E Chu, Martin Sjöström, Emily A Egusa, et al.
The Journal of Urology
|
October 25, 2021
Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons
Meera R Chappidi, Heiko Yang, Maxwell V Meng, et al.
BMC Cancer
|
November 19, 2023
Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer
John L Gore, Erika M Wolff, Bryan A Comstock, et al.
European Urology Oncology
|
June 30, 2026
Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab
Kevin R Reyes, Ryan Zhu, Cameron Herberts, et al.
Nature Communications
|
June 17, 2025
Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression
Heiko Yang, Hanbing Song, Elizabeth Yip, et al.
Cancers
|
April 13, 2024
Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry
Seyedeh-Sanam Ladi-Seyedian, Alireza Ghoreifi, Badrinath Konety, et al.
Page
of 9